By Sameer Shah • Darshan Engineer • Dhara Ganatra
CRDMO 2.0: From Mastering the Process to Mastering New Technologies
India’s pharma industry is entering a new era of Pharma R&D Outsourcing, aiming to capture a larger share of the $302 billion global CRDMO market by 2028. While India currently holds just 3.6% of the global market, opportunities abound as innovators diversify supply chains post-COVID.
Indian pharma has come a long way, from being an ancillary supplier to the dominant low-cost generic manufacturer of the world. It is now time for Indian companies to chart the next leg of value addition by moving up the value chain and becoming more strategically aligned to innovators both large and small.
The global CRDMO market is a $300 bn opportunity where India still has a relatively small market share of ~3.6%. However, the stars seem to be aligning in the form of regulations, reorganization of supply chains and capability/ capacity building by Indian companies to address this massive opportunity.
In this note we deep dive into the evolution of the CRDMO market and the potential for wealth creation. Indian companies have a right to win in the segment and the enablers seem to be in place.
Be prepared to hear a lot more about biologics, peptides, ADCs, oligonucleotides amongst many other new technologies.
Click here to read our in-depth Deep Dive.
#MegaTrends #PharmaInnovation #CRDMO #Inflexion Point #Investing #ValueQuest